Drug Profile
Bone disorder therapeutics - Emisphere/Roche
Latest Information Update: 14 Dec 2020
Price :
$50
*
At a glance
- Originator Emisphere Technologies; Roche
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 15 Feb 2006 Roche has initiated a clinical trial to evaluate a second small molecule compound for Bone disorders
- 05 Jul 2005 Phase-I clinical trials in Bone disorders in USA (PO)